Physician profile
Beth N Sweney
NPI 1689136434
$617,424.68
in general payments reported to CMS, 2019-2025
34 companies · $203K in 2025
The $203K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39K · 2022: $88K · 2023: $145K · 2024: $143K · 2025: $203K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $268K · Travel and Lodging: $156K · Consulting Fee: $41K · Food and Beverage: $24K · Education: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $268,095.00 |
| Travel and Lodging | $155,887.91 |
| Consulting Fee | $41,292.58 |
| Food and Beverage | $24,467.35 |
| Education | $722.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524,792.31 | 2021-2025 | |
| Ucb, INC. | $56,915.06 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $9,827.75 | 2021-2025 | |
| Incyte Corporation | $5,439.15 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $4,886.88 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $3,237.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,201.71 | 2021-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,129.08 | 2021-2022 | |
| Janssen Biotech, INC. | $1,447.58 | 2021-2025 | Tremfya, Remicade, Stelara |
| Amgen INC. | $1,171.50 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $872.87 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $659.95 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $642.58 | 2021-2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.78 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $432.21 | 2022-2024 | Vtama |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $413.37 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $390.29 | 2021-2023 | |
| Leo Pharma INC. | $382.89 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $272.61 | 2021-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $224.23 | 2021-2022 | |
| Organon LLC | $126.74 | 2025 | Vtama |
| Bioventus LLC | $61.20 | 2025 | Xcell, Durolane |
| Fresenius Kabi USA, LLC | $57.28 | 2023-2025 | |
| Nabriva Therapeutics, Plc | $35.40 | 2021 | |
| Vyne Pharmaceuticals INC. | $30.85 | 2021 | |
| Sandoz INC. | $27.69 | 2024 | Hyrimoz |
| Strata Skin Sciences, INC. | $26.85 | 2025 | Xtrac |
| Almirall LLC | $24.55 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.38 | 2021 | |
| Genentech USA, INC. | $16.96 | 2023 | Xolair |
| Mayne Pharma Commercial LLC | $16.49 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.43 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $14.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Sweney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.